Plasminogen activator entrapped within injectable alumina: a novel approach to thrombolysis treatment
- 191 Downloads
A major obstacle in the development of new enzyme-based thrombolytic systems is their low stability and extremely short half-life (usually, less than 2–6 min of circulation half-life), which requires their administration in large doses to obtain therapeutic effects, and as a consequence, inevitably leads to a significant incidence of hemorrhagic complications. Here we point to a potential solution of this problem by developing a new family of injectable composites for thrombolysis: plasminogen activator entrapped within alumina, where alumina is a pertinent drug carrier developed to prolong activity in vivo and to reduce the total administered dose of the drug necessary for the treatment, and hence its side effects.
KeywordsSol–gel synthesis Plasminogen activator Thrombolytic effect Entrapment
- 12.Bennett W, Paoni N, Keyt B, Botstein D, Jones AJS, Presta L, Wurm FM, Zoller MJ (1991) J Biol Chem 266:5191Google Scholar
- 13.Lijnen HR, Collen D (1991) Thromb Haemost 66:88Google Scholar
- 14.Bangert K, Johnsen AH, Christensen U, Thorsen S (1993) Biochem 291:623Google Scholar